Transcripts
DR. LINGWOOD:
Lastly, in terms of what can we
do about HUS in terms of a therapy, this is our
approach. I told you the lipid part is
important, but Gb3 is insoluble. What we've
done is put this group on here instead of the
fatty acid. The fatty acid is important, but
we've put this rigid globular cage-like
structure, and this is the molecular
characterization of the compound. By generating
this Gb3, the analogue becomes water soluble.
But this structure now inhibits
verotoxin Gb3 binding. Whereas I said, if you
just take this sugar part, that has no
inhibition here. So this is a water soluble
effective inhibitor of verotoxin. That's our
approach.
